Skip to Content

'
Garth Powis, D. Phil.

Present Title & Affiliation

Primary Appointment

David Bruton, Jr. Chair, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor and Chair, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Director, Center for Targeted Therapy, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
Barnhart Family Distinguished Award in Targeted Therapies, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Garth Powis is leading the charge to coordinate all stages of the drug discovery and development process at The University of Texas M. D. Anderson Cancer Center. As director of the Center for Targeted Therapy and professor and chairman of the Department of Experimental Therapeutics, he believes that the academic environment is ideal for initiating and developing new therapies.

Since his recruitment to M. D. Anderson in 2005, Dr. Powis is steadily working to make the dream of personalized medicine a reality. The establishment of the Center for Targeted Therapy, a state-of-the-art facility slated for completion in 2010, will allow researchers and clinicians alike the ability to design new, specific and more effective drugs with less toxicity, targeted for individualized therapy. It is a mission that begins with a concept to identify molecular and genetic targets specific to each patient, continues with drug discovery and development and is followed by clinical trials. Bringing novel therapeutic and preventive drugs from the bench to the bedside, quicker than ever before, is his ultimate goal for the Center for Targeted Therapy.

A pioneer of the targeting of signaling pathways for cancer drug discovery, Dr. Powis is the author of four books. He has published more than 350 peer-reviewed articles and holds 11 patents in the area of cancer drug discovery and development. Dr. Powis is a member of the editorial board for several leading scientific publications including the Journals of Molecular Pharmacology, Molecular Cancer Therapeutics, Cancer Pharmacology and Therapeutics and Clinical Cancer Research. His research interests include mechanism of action of new anti-cancer drug, inhibition of P13K/AKT survival signaling and inhibition of redox and hypoxia signaling in cancer and inhibiting KRAS signaling.  He has developed 3 cancer drugs, a thioredoxin inhibitor, a P13K inhibitor and a HIF-1alpha inhibitor that are currently in early clinical trial.

Research Interests

Exploiting Tumor Stress Response for Cancer Therapy

Solid tumors exist in a stressed environment for cell growth. In order to survive, cancer cells initiate specific adaptive and constitutive changes allowing them to adapt to the hostile hypoxic environment, escape cell death and increase formation of new blood vessels and metastasis. All of these responses lead to highly aggressive tumors that are resistant to therapy. In order to identify novel targets for therapeutic intervention that is applicable to a wide variety of tumor types, our lab studies the mechanisms that enable cancer cells to survive stress.

Please visit the Powis Lab.

Education & Training

Degree-Granting Education

1970 Merton College, Oxford, United Kingdom, D. Phil., Biochemistry and Pharmacology
1967 Birmingham University, England, United Kingdom, B.Sc., Hons. (1st Class), Biochemistry and Pharmacology

Selected Publications

Peer-Reviewed Original Research Articles

1. Kim YH, Coon A, Baker AF, Powis G. Antitumor agent PX-12 inhibits HIF-1a protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase. Cancer Chemother Pharmacol 68(2):405-13, 8/2011. e-Pub 11/11/2010. PMCID: PMC3107346.
2. Koh MY, Lemos R, Liu X, Powis G. The hypoxia associated factor (HAF) switches cells from HIF-1{alpha} to HIF-2{alpha} dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer Res 71(11):4015-27, 6/1/2011. e-Pub 4/21/2011. PMID: 21512133.
3. Kim YW, Liu TJ, Koul D, Tiao N, Feroze AH, Wang J, Powis G, Yung WK. Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM. Neuro Oncol 13(4):367-75, 4/2011. PMID: 21430111.
4. Ahad AM, Zuohe S, Du-Cuny L, Moses SA, Zhou LL, Zhang S, Powis G, Meuillet EJ, Mash EA. Development of sulfonamide AKT PH domain inhibitors. Bioorg Med Chem 19(6):2046-54, 3/15/2011. e-Pub 2/1/2011. PMCID: PMC3088502.
5. Schwartz DL, Bankson J, Bidaut L, He Y, Williams R, Lemos R, Thitai AK, Oh J, Volgin A, Soghomonyan S, Yeh HH, Nishii R, Mukhopadhay U, Alauddin M, Mushkudiani I, Kuno N, Krishnan S, Bornman W, Lai SY, Powis G, Hazle J, Gelovani J. HIF-1 dependent stromal adaptation to ischemia mediates in vivo tumor radiation resistance. Mol Cancer Res 9(3):259-70, 3/2011. e-Pub 3/1/2011. PMCID: PMC3077053.
6. Gwak HS, Shingu T, Chumbalkar V, Hwang YH, DeJournett R, Latha K, Koul D, Alfred Yung WK, Powis G, Farrell NP, Bögler O. Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma. Int J Cancer 128(4):787-96, 2/15/2011. PMCID: PMC2990813.
7. Ihle NT, Powis G, Kopetz S. PI-3-Kinase Inhibitors in Colorectal Cancer. Curr Cancer Drug Targets 11(2):190-8, 2/2011. PMID: 21158718.
8. Morrow JK, Du-Cuny L, Chen L, Meuillet EJ, Mash EA, Powis G, Zhang S. Recent development of anticancer therapeutics targeting the AKT pathway. Recent Pat Anticancer Drug Discov 6(1):146-59, 1/2011. PMID: 21110830.
9. Poindexter NJ, Williams RR, Powis G, Jen E, Caudle AS, Chada S, Grimm EA. IL-24 is expressed during wound repair and inhibits TGFalpha induced migration and proliferation of keratinocytes. Exp Dermatol 19(8):714-22, 8/2010. e-Pub 6/2010. PMID: 20545760.
10. Schwartz DL, Bankson JA, Lemos R, Lai SY, Thittai AK, He Y, Hostetter G, Demeure MJ, Von Hoff DD, Powis G. Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther 9(7):2057-67, 7/2010. e-Pub 6/2010. PMCID: PMC2935253.
11. Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, Ronen SM, Kirkpatrick DL, Powis G, Yung WK. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol 12(6):559-569, 6/2010. PMCID: PMC2940638.
12. Ihle NT, Powis G. Inhibitors of phosphatidylinositol-3-kinase in cancer therapy. Mol Aspects Med 31(2):135-144, 4/2010. e-Pub 2/2010. PMCID: PMC2877630.
13. Meuillet EJ, Zuohe S, Lemos R, Ihle N, Kingston J, Watkins R, Moses SA, Zhang S, Du-Cuny L, Herbst R, Jacoby JJ, Zhou LL, Ahad AM, Mash EA, Kirkpatrick DL, Powis G. Molecular pharmacology and antitumor activity of PHT-427, a Novel AKT/PDPK1 pleckstrin homology domain inhibitor. Mol Cancer Ther 9(3):706-717, 3/2010. e-Pub 3/2010. PMCID: PMC2837366.
14. Koh M and Powis G. HAF: the new player in oxygen-independent HIF-1 alpha degradation. Cell Cycle 8(9):1359-1366, 5/2009. PMCID: PMC2700049.
15. Bartholomeusz G, Cherukuri P, Kingston J, Cognet L, Lemos R, Leeuw TK, Gumbiner-Russo L, Weisman RB, Powis G. In-vivo therapeutic silencing of HIF-1(alpha) using single-walled carbon nanotubes noncovalently coated with siRNA. Nano Res 2(4):279-291, 4/17/2009. PMCID: PMC2801079.
16. James BP, Staatz WD, Wilkinson ST, Meuillet E, Powis G. Superoxide dismutase is regulated by the LAMMER kinase in Drosophila and human cells. Free Radic Biol Med 46(6):821-827, 3/15/2009. e-Pub 12/24/2008. PMCID: PMC2699669.
17. Ihle NT, Lemos R, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL, Powis G. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69(1):143-150, 1/2009. PMCID: PMC2613546.
18. Ihle NT, Lemos R, Schwartz D, Oh J, Halter RJ, Wipf P, Kirkpatrick L, Powis G. Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity. Mol Cancer Ther 8(1):94-100, 1/2009. PMCID: PMC2633941.
19. Ihle NT and Powis G. Take your PIK: Phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol Cancer Ther 8(1):1-9, 1/2009. PMCID: PMC2775557.
20. Koh MY, Spivak-Kroizman TR, Powis G. HIF-1 regulation: not so easy come easy go. Trends Biochem Sci 33(11):526-534, 9/2008. PMID: 18809331.
21. Koh MY, Darnay BG, Powis G. Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation. Mol Cell Biol 28(23):7081-95, 1/2008. PMCID: PMC2593390.
22. Koh MY, Spivak-Kroizman T, Venturini S, Welsh S, Williams RR, Kirkpatrick DL, Powis G. Molecular Mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia inducible factor-1 (alpha). Mol Cancer Ther 7(1):90-100, 2008. PMID: 18202012.

Editorials

1. Koh MY, Spivak-Kroizman TR and Powis G. Inhibiting the hypoxia response for cancer therapy: the new kid on the block. Clin Cancer Res 15(19):5945-5946, 10/2009. e-Pub 9/2009. PMCID: PMC2760048.
2. Powis G, Ihle NT, Yung WK. Inhibiting PI-3-K for glioma therapy. Cell Cycle 8(3):335-337, 2/1/2009. e-Pub 2/1/2009. NIHMSID: NIHMS200822.

Last updated: 8/31/2011